Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > ATNX Athenex > Detailed Quotes

ATNX Athenex

Watchlist
0.955
+0.325+51.61%
Close 08/05 16:00 ET
0.940
-0.015-1.57%
Post Mkt Price 08/05 19:59 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
0.996
Open
0.962
Turnover
13.04M
Low
0.840
Pre Close
0.630
Volume
13.75M
Market Cap
116.14M
P/E(TTM)
Loss
52wk High
3.910
Shares
121.61M
P/E(Static)
Loss
52wk Low
0.405
Float Cap
80.04M
Bid/Ask %
80.00%
Historical High
21.110
Shs Float
83.81M
Volume Ratio
8.47
Historical Low
0.405
Dividend TTM
--
Div Yield TTM
30
P/B
9.74
Dividend LFY
--
Div Yield LFY
3141.36%
Turnover Ratio
16.41%
Amplitude
24.69%
Avg Price
0.948
Lot Size
1
Float Cap
80.04M
Bid/Ask %
80.00%
Historical High
21.110
Shs Float
83.81M
Volume Ratio
8.47
Historical Low
0.405
Dividend TTM
--
P/B
9.74
Dividend LFY
--
Turnover Ratio
16.41%
Amplitude
24.69%
Avg Price
0.948
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company’s Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.
CEO: Lau F.R.C.P., M.B.B.S., M.D., Ph.D., Yiu-Nam
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top